In patients with ischemic mitral regurgitation requiring mitral valve replacement (MVR), the choice of the prosthesis type is crucial. The exercise hemodynamic and functional capacity performance in patients with contemporary prostheses have never been investigated. To compare exercise hemodynamic and functional capacity between biological (MVRb) and mechanical (MVRm) prostheses.
A growing body of evidence is challenging the long-standing trend favoring valve repair over mitral valve replacement (MVR) in patients with chronic ischemic mitral regurgitation (IMR). [1] [2] [3] [4] Consequently, it seems reasonable to consider chordal-sparing MVR in patients with IMR. 5 Current guidelines for prosthetic heart valve selection recommend either type of prosthetic valve for patients aged 60 to 70 years and mechanical prosthetic valves for patients younger than 60. 6, 7 The comparison of biological versus mechanical prostheses has been already addressed by 2 trials 8, 9 which, however, included the old generation models of prosthetic valves. On the other hand, retrospective analysis on contemporary prostheses investigated patient functional status and hemodynamics by using resting Doppler echocardiography. [10] [11] [12] [13] [14] [15] However, resting echocardiographic parameters are not representative of the patient's daily activities. Exercise stress echocardiography (ESE) represents a more suitable and robust method to evaluate mitral valve hemodynamics and, along with 6-minute walking test (6-MWT), may also provide incremental value for risk stratification of patients with valvular diseases. [16] [17] [18] In a high-risk group of patients, such those with IMR, it is essential to optimize the hemodynamic and functional outcome. In this regard, the choice of the prosthesis (biological versus mechanical) seems to be a crucial decision, but there are few data to guide decision-making. 14, 15 The aim of this study was, therefore, to compare the exercise hemodynamic performance and functional capacity in patients with IMR who underwent chordalsparing MVR with contemporary biological (MVRb) or mechanical (MVRm) prostheses and coronary artery bypass grafting.
METHODS

Study Population
We reviewed data of 155 consecutive patients with IMR undergoing MVR and coronary artery bypass grafting, at Ospedale Papa Giovanni XXIII, between January 2007 and June 2013. The definition of IMR was (1) mitral regurgitation >1 week after myocardial infarction; (2) >1 left ventricular (LV) segmental wall motion abnormalities; (3) significant coronary artery disease (≥75% stenosis of ≥1 coronary vessel) in the area creating the wall motion abnormality; (4) structurally normal mitral valve leaflets and chordae tendineae; and (5) type IIIb Carpentier classification, with or without annular dilatation. [19] [20] [21] The choice between bioprosthesis versus mechanical prosthesis was a shared decision between the surgeon and patient, based on age, life expectancy, preference, and indication/contraindication for warfarin therapy. 6, 22, 23 From the whole sample, we excluded 55 (35%) patients. A complete list of exclusion criteria is shown in Figure 1 . Early mortality was observed in 4 (5%) patients (MVRm=2; MVRb=2, p=not significant). Late mortality was observed in 4 (5%) patients (MVRm=2; MVRb=2, p=not significant). These 8 patients who died were excluded from the study population because they did not have the chance to undergo ESE. Six patients were also excluded because unable to complete ESE. Final study sample was composed of 86 patients (MVRm: n=45, 52% and MVRb: n=41, 48%), on whom we performed a longitudinal data analysis of 2 assessments only (preoperative: clinical, 6-MWT, and resting echocardiography; last follow-up: clinical, 6-MWT, resting, and exercise echocardiography; Figure 1 ).
Postoperative mortality and adverse events (ie, including stroke, bleeding, endocarditis, dialysis, reoperation, valve thrombosis, readmission for cardiac cause, heart failure, and sepsis or deep wound infection) data were collected. Both groups received the same preoperative, operative, and postoperative care. Follow-up was completed in all patients.
The study complies with the Declaration of Helsinki and was approved by the Ethical Committee of our Institution. All the patients signed an informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
WHAT IS NEW?
• In patients with ischemic mitral regurgitation, mitral valve replacement with a mechanical valve was associated with better improvement in mitral valve hemodynamics (larger effective orifice areas and lower gradients) and patient's functional capacity as reflected by the larger increase in 6-minute walking test distance.
• Prosthesis-patient mismatch has a detrimental impact on the hemodynamic and functional outcomes of patients with ischemic mitral regurgitation undergoing mitral valve replacement.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Recent randomized trials suggest that mitral valve replacement may be superior to mitral valve repair for the treatment of ischemic mitral regurgitation. The present study suggests that when replacement is indicated in such patients, it may be preferable to select a mechanical valve rather than a bioprosthetic valve to optimize postoperative valve hemodynamic and patient's functional status.
• In patients with ischemic mitral regurgitation and heart failure, it is essential to implant a prosthetic valve that has superior hemodynamics and provides the largest possible effective orifice area.
• Larger studies with longer follow-up including exercise hemodynamic, quality of life, and survival data are required to confirm the superiority of mechanical valves for the surgical treatment of ischemic mitral regurgitation.
Surgical Technique
The mitral prostheses were inserted with total preservation of subvalvular apparatus. Mechanical prostheses were implanted in the antianatomic position, rotating the valve as needed. 24 All patients underwent concomitant coronary artery bypass grafting with complete revascularization in all patients (more details are given in Surgical Technique section in Methods in the Data Supplement).
Preoperative Assessment
A physician performed the assessment of the 6-MWT 25 distance, along with resting standard 2-dimensional and Doppler echocardiogram.
Perioperative Management
After surgery, the mode of initiation of anticoagulation was based by using subcutaneous unfractionated heparin until therapeutic international normalized ratio was achieved. Additional antiplatelet agent was initiated and maintained in both group 22, 26 (more details are given in Perioperative Management section in Methods in the Data Supplement).
Resting and ESE Protocol
Echocardiographic measurements were indexed to body surface area, and the Doppler tracings were averaged over 3 to 5 beats. The following parameters were measured: LV end-diastolic and end-systolic diameters, LV ejection fraction, mitral regurgitation severity assessed with the vena contracta width, LV diastolic function, LV stroke volume was determined by multiplied the LV outflow tract area to the time integral of the outflow tract velocity (pulsed-wave Doppler), cardiac output (more details are given in Resting and ESE Protocol section in Methods in the Data Supplement).
Mitral Valve Hemodynamics
The peak and mean transmitral pressure gradients were calculated. Mitral valve effective orifice area (EOA) was determined by the continuity equation. Systolic pulmonary arterial pressure (SPAP) was calculated by adding the systolic right ventricular pressure derived from the tricuspid regurgitation to the estimated right atrial pressure 27 (more details are given in Mitral Valve Hemodynamics section in Methods in the Data Supplement).
Statistical Analysis
Statistical analyses were performed with a commercially available software program (SPSS 16; IBM Ltd). Considering relatively small sample size per group and non-normal distribution, comparisons between groups for continuous variables were made by unpaired 2-sided t test or nonparametric Mann-Whitney test as appropriate; comparisons for categorical variables were performed using the χ 2 or Fisher exact test. Changes in echocardiographic parameters and 6-MWT distance between baseline (pre-operative) and follow-up evaluation were tested by paired t test or Wilcoxon matched-pairs signed rank-sum test. To identify joint predictors of 6-MWT at follow-up or changes in 6-MWT (postoperative-preoperative), linear regression and multiple linear regression models were used. Multivariable models were built using a backward stepwise strategy. Candidate variables for the final multivariable model selection were those with a P value <0.10 at the univariate analysis. The final model was built with demographic, clinical, and rest and stress echocardiographic measures as joint variables; in multivariable analysis, coefficients of determination (R 2 ) were used to determine strength of the association between a combination of echocardiographic parameters of LV function, cardiovascular hemodynamics or prosthesis characteristics, and the dependent variable (ie, 6-MWT). An F test of the overall significance was used to compare predictive accuracy of heretofore identified models. Median follow-up was 36 months (25th-75th percentiles=27-51). Cardiac-related hospitalization-free survival was analyzed using actuarial Kaplan-Meier curves; log-rank test for significant differences between the 2 groups.
RESULTS
Preoperative Data
Atrial fibrillation was present in 18 (21%) patients of the total sample without any difference between MVRb and MVRm. Six-minute walking test and body surface area were similar between the 2 groups. Medical therapy was similar between the 2 groups, except for the preoperative use of nitrates that was more frequent in the MVRm (P=0.04; Complete data are reported in Table 1 )
Operative Data
A bioprosthesis was implanted in 41 (48%) patients, whereas 45 (52%) of the patients received a mechanical prosthesis (Table 2 ). In the MVRb group, 3 (7%) patients received a Carpentier-Edwards Perimount Pericardial bioprosthesis size 25 mm, 18 (44%) patients received size 27, 12 (29%) size 29, and 8 patients (20%) size 31 mm. In the MVRm group, a mechanical St Jude Medical valve, size 27 mm, was used in 9 (20%) patients; a size 29 was used in 16 (36%) and a size 31 in 6 (14%) patients; a Carbomedics size 27 mm valve was used in 7 (16%) patients, a size 29 in 3 (7%), and a size 31 in 3 (7%) of the patients (complete operative data are reported in Table 2 ).
Preoperative and Follow-Up Resting Echocardiographic Data
The median follow-up time (ie, time from surgery to the functional and echocardiographic assessment) was 25 months (interquartile, 14-38 months) without significant difference between the 2 groups (P=0.23). Stroke volume increased in the MVRm, whereas it decreased in the MVRb group, without any significant difference within and between the 2 groups (MVRm: from 55±06 to 57±16 mL; MVRb: from 55±11 to 53±9 mL; P=0. 13 Table 3 ).
Follow-Up Exercise Echocardiographic Data
At peak exercise, cardiac index significantly increased to a larger extent in MVRm group when compared with MVRb (from 2.3±0. 6 Table 4 ). Exerciseinduced changes in transmitral mean and peak pressure gradients were significantly higher in MVRb when compared with MVRm (Table 4 ). In addition, exercise SPAP was significantly higher in MVRb, when compared with MVRm (P=0.001; Table 4 ; Complete data are reported in Table 4 ).
Functional Capacity Data
The 6-MWT distance improved from preoperative (baseline) to follow-up in MVRm group (from 242±43 to 290±50 m; P=0.001), whereas it remained similar in the MVRb group (from 250±40 to 220±44 m; P=0.13). The 6-MWT distance at follow-up and the absolute change from preoperative baseline to follow-up were significantly higher in the MVRm, when compared with MVRb (P<0.05 and P<0.0001, respectively; Figure 2) . When adjusted by type of prosthesis implanted (mechanical or biological), a significant correlation was found between exercise i-EOA ( Figure 3A ) and exercise SPAP ( Figure 3B ) with changes in 6-MWT, from preoperative baseline to follow-up.
Exercise i-EOA and exercise SPAP also correlated with the 6-MWT distance at follow-up (Figures 4 and 5 ), but these correlation were no longer significant after adjusting by type of prosthesis implanted (Figures I and II in the Data Supplement). Table 5 presents the univariable and multivariable predictors of 6-MWT at follow-up and changes in 6-MWT (ie, difference between preoperative and follow-up). After adjustment for preoperative 6-MWT distance, exercise SPAP, and i-EOA, MVRm remained jointly associated with both 6-MWT at follow-up and changes in 6-MWT. Having a moderate-to-severe PPM was not associated to the 6-MWT assessed at follow-up neither at the simple linear regression analysis nor at the multivariable analysis (Table 5) . However, patients with moderate-to-severe PPM were able, on average, to walk 12 m less than patients with no or mild PPM. This difference was significantly associated to the 6-MWT delta (ie, the difference between distance at follow-up and preoperative) according to the univariate analysis, but PPM severity was no longer significantly associated with 6-MWT delta when the analysis was controlled by the type of prosthesis implanted (additional results are given in Data Analysis in the Data Supplement).
Predictors of Functional Capacity
Clinical Outcomes
Clinical data are reported in the Clinical Outcome section in the Data Supplement (Table I in Two historic randomized clinical trials compared outcomes after valve replacement with a first-generation porcine bioprostheses and the Bjork-Shiley mechanical valve. 8, 9 Hence, the ability to extrapolate these data to decisions made in modern practice is limited. The only data on contemporary prostheses are available from retrospective studies [10] [11] [12] 28, 29 which included aortic and mitral prostheses, along with differences in patients' baseline characteristics, making difficult to reach meaningful conclusions.
The evidence from the aforementioned studies favored biological prostheses over mechanical ones, specifically in patients ≥65 years old, in the light of comparable mortality, but lower bleeding risk. 8, 10 Kulik et al 30 reported improved survival and lower risk of major prosthetic-related adverse events in middle-aged patients with mechanical prostheses, when compared with bioprostheses. A propensity score-matched analysis by Kaneko et al 12 showed that the use of a bioprosthesis was a significant predictor of long-term mortality for patients undergoing MVR. In a large multicenter propensity-matched series of MVR, Chikwe et al 13 found no difference in the long-term survival between the 2 group; however, echocardiographic and functional data were not reported. Conversely, in our study, we have only analyzed patients with IMR and similar comorbidity profiles between MVRm and MVRb; moreover, ESE was used. 16 Previous literature reported that a reduced i-EOA represents a joint predictor of mortality after MVR. 14, 15 In our study, we observed a significant exercise reduction of i-EOA in the MVRb compared with the MVRm. This reduction was a joint predictor of change in 6-MWT at follow-up. On the contrary, a significant exercise increment of i-EOA was found in the MVRm, challenging the generally assumption which assume, in the aortic mechanical valves, an on/off phenomenon. 31 Many reasons, such as the type of effort or the method used for calculating the valve area, have been advocate, to explain this finding. 31 However, an on/off phenomenon cannot be translated to the mitral prostheses, in which the mechanism of valve opening is a complex interaction between left atrium and LV. Hobson et al 16 reported a significant dobutamine stress increase of the EOA. The exercise increment of i-EOA we observed in the MVRm could reflect a higher rate of change of valve leaflet opening and closing, along with a concomitant increase of stroke volume.
Moreover, the worsening hemodynamic and functional capacity of MVRb could be partially explained by their higher incidence of moderate PPM. However, in the multivariable analysis, PPM was not an independent predictor neither of 6-MWT nor of 6-MWT delta.
The reasons underlying the better exercise hemodynamics in the MVRm are unclear. The hemodynamic performance of the prostheses correlates to the total cross-sectional area effectively available for blood flow. 23, 32 Bioprostheses have a central area available for flow, surrounded by the area occupied by the supporting stents, which may further steal some effective area for blood flow. 32 Conversely, bileaflet mechanical prostheses have a small central orifice and 2 larger semicircular orifices laterally. The greater cross-sectional area available for flow may account for the larger i-EOA in MVRm. This may allow for larger increase in transmitral flow and lesser increase in gradients and pulmonary arterial pressures during exercise. These favorable hemodynamic features observed in the MVRm may translate into better functional capacity. Furthermore, the durability of mitral bioprostheses is limited because of the high mechanical stress during systole 33 and this may compromise their outcome. However, further studies are needed to determine the underlying fac- 
Clinical Implications
For patients who require MVR, the prosthesis can significantly influence outcome. 34 Primary goal of valve surgery should be relief of symptoms, improvement in functional capacity, and a favorable impact on mortality and morbidity, 15, 35 particularly in patients with heart failure. In these patients, persistence of high postoperative SPAP will ultimately lead to an increased cardiovascular morbidity. 36 When MVR is indicated, the surgeon should implant a prosthesis with the largest possible i-EOA to optimize the hemodynamic and functional outcomes ( Figure 6 ).
23
Strengths and Limitations
This is the only study which addresses the exercise hemodynamic and the functional capacity in a consecutive highly homogeneous series of patients with ischemic cardiomyopathy undergoing MVR with contemporary prostheses. However, this is a singlecenter and retrospective study; it is thus subset to potential selection bias. Although this potentially increases the risk of unmeasured confounders, it also enhances consistency in preoperative evaluation, surgical techniques, and follow-up assessment of enrolled patients.
We reported only a single measurement of 6-MWT and ESE, rather than repeated measures over time; it would have been interesting to have a longitudinal data analysis of serial assessments.
We performed 6-MWT, rather than cardiopulmonary exercise testing. However, 6-MWT is widely used in patients with heart failure and is easier to apply in this population.
We do not have the data on preoperative myocardial viability in the 2 groups. Thus, it is unknown whether potential absence of ventricular remodeling might have influenced the results between the 2 groups. Furthermore, it would be interesting to know if a potential progression of coronary disease contributed to the different outcomes between the 2 types of prostheses. Given that we performed multiple comparison between MVRb and MVRm groups, type I error may be higher than 5%.
Conclusions
In patients with ischemic cardiomyopathy, mechanical prostheses are associated with better exercise hemodynamics and functional capacity compared with bioprostheses. These data provide support to the use of mechanical rather than biological valve in these patients ( Figure 6 ). However, larger studies with longer followup including hemodynamic, quality of life, and survival data are required to confirm these results. 
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